Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Invested Capital (2019 - 2025)

BridgeBio Pharma's Invested Capital history spans 7 years, with the latest figure at -$79.3 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 89.13% year-over-year to -$79.3 million; the TTM value through Dec 2025 reached -$79.3 million, up 89.13%, while the annual FY2025 figure was -$79.3 million, 89.13% up from the prior year.
  • Invested Capital for Q4 2025 was -$79.3 million at BridgeBio Pharma, down from $84.6 million in the prior quarter.
  • Across five years, Invested Capital topped out at $358.1 million in Q1 2021 and bottomed at -$1.8 billion in Q2 2025.
  • The 5-year median for Invested Capital is -$1.1 billion (2022), against an average of -$870.7 million.
  • The largest annual shift saw Invested Capital crashed 497.32% in 2022 before it soared 106.94% in 2025.
  • A 5-year view of Invested Capital shows it stood at -$867.0 million in 2021, then plummeted by 43.41% to -$1.2 billion in 2022, then fell by 8.02% to -$1.3 billion in 2023, then soared by 45.72% to -$729.0 million in 2024, then skyrocketed by 89.13% to -$79.3 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Invested Capital are -$79.3 million (Q4 2025), $84.6 million (Q3 2025), and -$1.8 billion (Q2 2025).